The important thing to notice is that these shorts have little to no following, and Adam Feuerstein is called in only when the shorts are at their breaking point, as evidenced by Utopian Capital being massively underwater in their short position with the CYDY shares moving up week after week. Any shareholder selling Monday will become a victim to one of the biggest cons in biotech, perpetrated by the self-professed “Night King of Biotech.” In all likelihood, this con will approach $10 billion because it has become clear from the $10 billion movements in GILD’s market capitalization that a COVID-19 treatment is worth about that much. Investors should thank Adam Feuerstein for his great research because a $10 billion market capitalization puts a $20 price target on CYDY stock.